

6-K Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â Â FORM 6-K Â Â
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the
month of January 2025 Commission File Number: 001-40299 Â Â Achilles Therapeutics plc (Exact name of registrant as
specified in its charter) Â Â 245Hammersmith Road London W6 8PW United Kingdom Tel: +44(0)20 8154 4600
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrantâ€™s Principal
Executive Offices) Â Â Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F. Form 20-Fâ€,â˜'â€fâ€fâ€fForm40-Fâ€,â˜' Â Â Resignations from Achilles Board of Directors
On DecemberÂ 31, 2024, Julie Oâ€™Neill, Michael Giordano and Bernhard Ehmer each resigned as a director from the
board of directors (theâ€œBoardâ€) of Achilles Therapeutics plc (â€œAchillesâ€ or the â€œCompanyâ€), effective
immediately. Ms.Â Oâ€™Neill had served on the Board since 2021 and was a member of the Audit Committee of the
Board. Dr.Â Giordano had served on the Board since 2018 and was a member of the Remuneration Committee of the
Board, Nominating Committee of the Board, and ResearchÂ & Development Committee of the Board. Dr.Â Ehmer had
served on the Board since 2022 and was a member of the ResearchÂ & Development Committee of the Board. Each of
Ms.Â Oâ€™Neill, Dr.Â Giordano and Dr.Â Ehmerâ€™s resignations is not a result of any disagreement with the
Company on any matter relating to the Companyâ€™s operations, policies or practices and follows the Companyâ€™s
press release of DecemberÂ 24, 2024 announcing a planned decrease in the size of the Board. This Report on Form 6-K,
including the exhibit hereto, is incorporated by reference into the Companyâ€™s filings under the Securities Act of
1933, as amended (the â€œSecurities Actâ€) including the Companyâ€™s Registration Statements on Forms F-3
(File No.Â 333-268239) and S-8 (File Nos. 333-278501, 333-270344, 333-263220, and 333-255063) to the extent not
superseded by information subsequently filed or furnished (to the extent the Company expressly states that it
incorporates such furnished information by reference) by the Company under the Securities Act or the Securities
Exchange Act of 1934, as amended. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized. Â Â Â ACHILLES THERAPEUTICS PLC Date: JanuaryÂ 6, 2025 Â Â By: Â /s/ Robert Coutts Â Â Â
Robert Coutts Â Â Â Chief Financial Officer